Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Non-Current Assets: 2012-2025

Historic Non-Current Assets for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to $76.4 million.

  • Enanta Pharmaceuticals' Non-Current Assets fell 0.53% to $76.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.4 million, marking a year-over-year decrease of 0.53%. This contributed to the annual value of $76.4 million for FY2025, which is 0.53% down from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported Non-Current Assets of $76.4 million as of FY2025, which was down 0.53% from $76.8 million recorded in FY2024.
  • Enanta Pharmaceuticals' 5-year Non-Current Assets high stood at $119.8 million for FY2021, and its period low was $39.5 million during FY2023.
  • For the 3-year period, Enanta Pharmaceuticals' Non-Current Assets averaged around $64.2 million, with its median value being $76.4 million (2025).
  • Its Non-Current Assets has fluctuated over the past 5 years, first spiked by 142.97% in 2021, then crashed by 46.82% in 2022.
  • Yearly analysis of 5 years shows Enanta Pharmaceuticals' Non-Current Assets stood at $119.8 million in 2021, then tumbled by 46.82% to $63.7 million in 2022, then slumped by 38.01% to $39.5 million in 2023, then skyrocketed by 94.51% to $76.8 million in 2024, then dropped by 0.53% to $76.4 million in 2025.